Compare Eli Lilly And Co (LLY) vs Paycom Software Inc (PAYC) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Paycom Software (PAYC) trades at $149.71, up 1.2% with a bullish technical signal supported by moving averages. The company shows strong profitability with 22.44% net income margin and 37.15% ROE, though recent Q3 2025 EPS slightly missed expectations. Recent developments include new asset management tool launches and board appointments, while analyst consensus sits at $151 price target with 47% buy ratings.

PAYC presents a balanced investment case with solid fundamentals and moderate valuation (P/E 17.12), though execution risks and competitive pressures in HCM software require monitoring. The stock's proximity to resistance at $152 suggests near-term consolidation potential, while earnings growth remains the key catalyst for further upside.